Dr. Ronald Hoffman, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1971)
- Years since graduation
- 55
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 56
Licensed in Illinois since 1995, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1971Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036091393 (first issued 1995; not renewed)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 56
- Services billed
- 252
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 194 | 51 |
| Established patient office or other outpatient visit, 40-54 minutes | 30 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 22 |
| Vonjo (pacritinib citrate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 18 payments worth $3,877 in total to this clinician.
| Sumitomo Pharma America, Inc. | $3,440 |
|---|---|
| Novartis Pharmaceuticals Corporation | $170 |
| Genzyme Corporation | $93.24 |
| Celgene Corporation | $88.38 |
| Blueprint Medicines Corporation | $39.85 |
| Incyte Corporation | $27.73 |
| Servier Pharmaceuticals LLC | $17.75 |
| Consulting Fee | $3,440 |
|---|---|
| Food and Beverage | $437 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. Sep 4, 2025 | Consulting Fee | $3,440 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $288,497 in research payments for these studies, mostly to the institutions running them.
- Evaluate the effects of Selinexor, an XPO1 inhibitor, on MF pro-inflammatory milieu and depletion of MF HSCs
Karyopharm Therapeutics Inc. - Differential effects of ruxolitinib and pacritinib on megakaryocyte development and transcriptomic signatures
Sobi, Inc - VON-USA-2024-2450
Sobi, Inc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.